Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raltitrexed + apatinib
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Hepatic Arterial Infusion
01
Overview
A combination therapy consisting of raltitrexed, an antineoplastic agent and folic acid antagonist that inhibits thymidylate synthase, and apatinib, a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2). This combination has been investigated for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis and metastatic colorectal cancer.
- Brand names
- AitanTomudex
- Other names
- apatinib mesylateraltitrexedum
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on raltitrexed + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raltitrexed + apatinib.